Product Code: GVR-4-68040-511-8
North America And Europe Sepsis Diagnostics Market Growth & Trends:
The North America and Europe sepsis diagnostics market size is anticipated to reach USD 1.24 billion by 2030 and is anticipated to expand at a CAGR of 7.3% during the forecast period, according to a new report by Grand View Research, Inc. North America experiences a significant prevalence of sepsis, making it a leading cause of hospital deaths. This high incidence drives the demand for effective diagnostic solutions. Favorable reimbursement policies also encourage healthcare providers to adopt advanced diagnostics, while increased awareness and public-private funding boost the development of innovative tools.
In Europe, stringent regulations ensure reliable sepsis testing methods are available, supporting market growth. The aging population, more susceptible to infections, further escalates the demand for tailored diagnostic solutions. In addition, the rising healthcare spending enhances access to advanced diagnostics across European countries.
The European Centre for Disease Prevention and Control (ECDC) reported in 2024 that HAIs affected around 4.5 million patients annually, with sepsis as a major consequence. In 2023, the UK government allocated approximately USD 12 million for antimicrobial resistance (AMR) research, directly aiding sepsis management initiatives. Moreover, projected federal funding for sepsis-related programs in the U.S. was expected to exceed USD 50 million in 2024, aimed at improving diagnostic technologies and reducing mortality rates associated with sepsis.
North America And Europe Sepsis Diagnostics Market Report Highlights:
- Based on product, blood culture media held over 30.0% market share in 2023, while assay kits and reagents are poised for lucrative growth from 2025 to 2030 onwards
- Microbiology led the technology segment in 2024, while molecular diagnostics are anticipated to witness the fastest rate of 9.3% over the forecast period
- Based on pathogen, bacterial sepsis held the largest market share in 2024, driven by significant mortality rates, rising HAIs, and technological advancements. It is also expected to grow at the fastest CAGR over the forecast period
- Based on testing, POC testing is expected to grow at a staggering 9.6% CAGR as laboratory testing led the testing segment
- Based on method, automated diagnostic methods are expected to grow at the fastest CAGR over the forecast period
- The U.S. dominated the North America sepsis diagnostics market as the shift to value-based care promotes early detection, while supportive reimbursement, increased awareness, and government initiatives enhance sepsis management innovations.
- The UK sepsis diagnostics market is expected to grow at the fastest rate of 8.1% over the forecast period in the Europe market
- In March 2024, BD collaborated with GOCC in Poland to enhance access to advanced bloodstream infection testing, deploying state-of-the-art microbiology equipment across over 150 hospitals and clinics for improved sepsis management
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Technology
- 1.2.3. Pathogen
- 1.2.4. Testing
- 1.2.5. Method
- 1.2.6. End Use
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. North America and Europe Sepsis Diagnostics Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
Chapter 4. North America and Europe Sepsis Diagnostics Market: Product Business Analysis
- 4.1. Product Market Share, 2024 & 2030
- 4.2. Product Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
- 4.4. Instruments
- 4.4.1. Instruments Market, 2018 - 2030 (USD Million)
- 4.5. Blood Culture Media
- 4.5.1. Blood Culture Media Market, 2018 - 2030 (USD Million)
- 4.6. Assay Kits and Reagents
- 4.6.1. Assay Kits and Reagents Market, 2018 - 2030 (USD Million)
- 4.7. Software
- 4.7.1. Software Market, 2018 - 2030 (USD Million)
Chapter 5. North America and Europe Sepsis Diagnostics Market: Technology Business Analysis
- 5.1. Technology Market Share, 2024 & 2030
- 5.2. Technology Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Technology, 2018 to 2030 (USD Million)
- 5.4. Microbiology
- 5.4.1. Microbiology Market, 2018 - 2030 (USD Million)
- 5.5. Molecular Diagnostics
- 5.5.1. Molecular Diagnostics Market, 2018 - 2030 (USD Million)
- 5.5.2. Polymerase Chain Reaction (PCR)
- 5.5.2.1. Polymerase Chain Reaction (PCR) Market, 2018 - 2030 (USD Million)
- 5.5.3. DNA Microarrays
- 5.5.3.1. DNA Microarrays Market, 2018 - 2030 (USD Million)
- 5.5.4. Syndromic Panel Testing
- 5.5.4.1. Syndromic Panel Testing Market, 2018 - 2030 (USD Million)
- 5.5.5. Others
- 5.5.5.1. Others Market, 2018 - 2030 (USD Million)
- 5.6. Immunoassays
- 5.6.1. Immunoassays Market, 2018 - 2030 (USD Million)
- 5.7. Flow Cytometry
- 5.7.1. Flow Cytometry Market, 2018 - 2030 (USD Million)
- 5.8. Others
- 5.8.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. North America and Europe Sepsis Diagnostics Market: Pathogen Business Analysis
- 6.1. Pathogen Market Share, 2024 & 2030
- 6.2. Pathogen Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Pathogen, 2018 to 2030 (USD Million)
- 6.4. Bacterial Sepsis
- 6.4.1. Bacterial Sepsis Market, 2018 - 2030 (USD Million)
- 6.4.2. Gram-positive Bacteria
- 6.4.2.1. Gram-positive Bacteria Market, 2018 - 2030 (USD Million)
- 6.4.3. Gram-negative Bacteria
- 6.4.3.1. Gram-negative Bacteria Market, 2018 - 2030 (USD Million)
- 6.5. Fungal Sepsis
- 6.5.1. Fungal Sepsis Market, 2018 - 2030 (USD Million)
- 6.6. Viral Sepsis
- 6.6.1. Viral Sepsis Market, 2018 - 2030 (USD Million)
- 6.7. Others
- 6.7.1. Others Market, 2018 - 2030 (USD Million)
Chapter 7. North America and Europe Sepsis Diagnostics Market: Testing Business Analysis
- 7.1. Testing Market Share, 2024 & 2030
- 7.2. Testing Segment Dashboard
- 7.3. Market Size & Forecasts and Trend Analysis, by Testing, 2018 to 2030 (USD Million)
- 7.4. Laboratory Testing
- 7.4.1. Laboratory Testing Market, 2018 - 2030 (USD Million)
- 7.5. PoC Testing
- 7.5.1. PoC Testing Market, 2018 - 2030 (USD Million)
Chapter 8. North America and Europe Sepsis Diagnostics Market: Method Business Analysis
- 8.1. Method Market Share, 2024 & 2030
- 8.2. Method Segment Dashboard
- 8.3. Market Size & Forecasts and Trend Analysis, by Method, 2018 to 2030 (USD Million)
- 8.4. Automated Diagnostics
- 8.4.1. Automated Diagnostics Market, 2018 - 2030 (USD Million)
- 8.5. Conventional Diagnostics
- 8.5.1. Conventional Diagnostics Market, 2018 - 2030 (USD Million)
Chapter 9. North America and Europe Sepsis Diagnostics Market: End Use Business Analysis
- 9.1. End Use Market Share, 2024 & 2030
- 9.2. End Use Segment Dashboard
- 9.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
- 9.4. Hospitals & Clinics
- 9.4.1. Hospitals & Clinics Market, 2018 - 2030 (USD Million)
- 9.5. Pathology & Reference Laboratories
- 9.5.1. Pathology & Reference Laboratories Market, 2018 - 2030 (USD Million)
- 9.6. Research Institutes and Others
- 9.6.1. Research Institutes and Others Market, 2018 - 2030 (USD Million)
Chapter 10. North America and Europe Sepsis Diagnostics Market: Regional Estimates & Trend Analysis
- 10.1. Regional Market Share Analysis, 2024 & 2030
- 10.2. Regional Market Dashboard
- 10.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
- 10.4. North America
- 10.4.1. North America Sepsis Diagnostics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 10.4.2. U.S.
- 10.4.2.1. Key Country Dynamics
- 10.4.2.2. Regulatory Framework
- 10.4.2.3. Competitive Insights
- 10.4.2.4. U.S. Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 10.4.3. Canada
- 10.4.3.1. Key Country Dynamics
- 10.4.3.2. Regulatory Framework
- 10.4.3.3. Competitive Insights
- 10.4.3.4. Canada Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 10.5. Europe
- 10.5.1. Europe Sepsis Diagnostics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 10.5.2. UK
- 10.5.2.1. Key Country Dynamics
- 10.5.2.2. Regulatory Framework
- 10.5.2.3. Competitive Insights
- 10.5.2.4. UK Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 10.5.3. Germany
- 10.5.3.1. Key Country Dynamics
- 10.5.3.2. Regulatory Framework
- 10.5.3.3. Competitive Insights
- 10.5.3.4. Germany Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 10.5.4. France
- 10.5.4.1. Key Country Dynamics
- 10.5.4.2. Regulatory Framework
- 10.5.4.3. Competitive Insights
- 10.5.4.4. France Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 10.5.5. Italy
- 10.5.5.1. Key Country Dynamics
- 10.5.5.2. Regulatory Framework
- 10.5.5.3. Competitive Insights
- 10.5.5.4. Italy Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 10.5.6. Spain
- 10.5.6.1. Key Country Dynamics
- 10.5.6.2. Regulatory Framework
- 10.5.6.3. Competitive Insights
- 10.5.6.4. Spain Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 10.5.7. Russia
- 10.5.7.1. Key Country Dynamics
- 10.5.7.2. Regulatory Framework
- 10.5.7.3. Competitive Insights
- 10.5.7.4. Russia Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 10.5.8. Norway
- 10.5.8.1. Key Country Dynamics
- 10.5.8.2. Regulatory Framework
- 10.5.8.3. Competitive Insights
- 10.5.8.4. Norway Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 10.5.9. Denmark
- 10.5.9.1. Key Country Dynamics
- 10.5.9.2. Regulatory Framework
- 10.5.9.3. Competitive Insights
- 10.5.9.4. Denmark Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 10.5.10. Sweden
- 10.5.10.1. Key Country Dynamics
- 10.5.10.2. Regulatory Framework
- 10.5.10.3. Competitive Insights
- 10.5.10.4. Sweden Sepsis Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 11. Competitive Landscape
- 11.1. Participant Overview
- 11.2. Company Market Position Analysis
- 11.3. Company Categorization
- 11.4. Strategy Mapping
- 11.5. Company Profiles/Listing
- 11.5.1. BD
- 11.5.1.1. Overview
- 11.5.1.2. Financial Performance
- 11.5.1.3. Product Benchmarking
- 11.5.1.4. Strategic Initiatives
- 11.5.2. bioMerieux SA
- 11.5.2.1. Overview
- 11.5.2.2. Financial Performance
- 11.5.2.3. Product Benchmarking
- 11.5.2.4. Strategic Initiatives
- 11.5.3. Thermo Fisher Scientific Inc.
- 11.5.3.1. Overview
- 11.5.3.2. Financial Performance
- 11.5.3.3. Product Benchmarking
- 11.5.3.4. Strategic Initiatives
- 11.5.4. Beckman Coulter, Inc. (Danaher Corporation)
- 11.5.4.1. Overview
- 11.5.4.2. Financial Performance
- 11.5.4.3. Product Benchmarking
- 11.5.4.4. Strategic Initiatives
- 11.5.5. F. Hoffmann-La Roche Ltd
- 11.5.5.1. Overview
- 11.5.5.2. Financial Performance
- 11.5.5.3. Product Benchmarking
- 11.5.5.4. Strategic Initiatives
- 11.5.6. Cepheid
- 11.5.6.1. Overview
- 11.5.6.2. Financial Performance
- 11.5.6.3. Product Benchmarking
- 11.5.6.4. Strategic Initiatives
- 11.5.7. Luminex Corp.
- 11.5.7.1. Overview
- 11.5.7.2. Financial Performance
- 11.5.7.3. Product Benchmarking
- 11.5.7.4. Strategic Initiatives
- 11.5.8. Koninklijke Philips N.V.
- 11.5.8.1. Overview
- 11.5.8.2. Financial Performance
- 11.5.8.3. Product Benchmarking
- 11.5.8.4. Strategic Initiatives
- 11.5.9. Bruker
- 11.5.9.1. Overview
- 11.5.9.2. Financial Performance
- 11.5.9.3. Product Benchmarking
- 11.5.9.4. Strategic Initiatives
- 11.5.10. Immunexpress Inc.
- 11.5.10.1. Overview
- 11.5.10.2. Financial Performance
- 11.5.10.3. Product Benchmarking
- 11.5.10.4. Strategic Initiatives